Brief History of Remedica, a leading pharmaceutical company in the European Union

Remedica's History

2017

2017

  • Nevalan®, a drug for acid related disorders, Entevirem®, an antiviral for systemic use, Rezavir®, an antiviral for systemic use, and Bradirem®, a cardiac therapy were registered successfully in Cyprus.
  • Remedica elected as the best Company in the Ascendis Health Group of Companies
2016

2016

Remedica became part of the Johannesburg-listed healthcare conglomerate Ascendis Health Ltd. As part of this development, Remedica integrated with the Ascendis Health Pharma-Med division and became an important and integral part of a stronger, international player.

2015

2015

  • Remedica won a place in the final top 10 best export companies across Europe (Ruban d’Honneur) at the European Business Awards.
  • The company was successfully inspected by the Iranian Authorities (IFDA)
2014

2014

  • The company was successfully inspected by the Japanese Authorities (PMDA)
  • Remedica received its 8th Export Award for Industry
2013

2013

  • Remedica’s new oncology facility begun operations. Imarem® (Imatinib), an anti-neoplastic agent, was registered in Cyprus
  • Successful inspection by the Brazilian Authorities (ANVISA)
  • The company has been included by the IN BUSINESS Magazine in its list of the fifty most socially responsible companies in Cyprus
  • Remedica announced the Pattihis Family Scholarship for the MSc Management Degree in the Department of Management Science and Innovation at University College London (UCL), UK
  • Remedica sponsored the Cyprus University of Technology “Open Access Author Fund” so that it’s library can offer open access to students to publish their research.